Development of a Nomogram-Based Tool to Predict Neurocognitive Impairment Among HIV-positive Charter Participants



Despite the widespread use of combination antiretroviral therapy (cART), HIV-associated neurocognitive impairment (NCI) persists in people living with HIV (PLWH). Studies have generated inconsistent results regarding etiological factors for NCI in PLWH. Furthermore, a user-friendly and readily available predictive tool is desirable in clinical practice to screen PLWH for NCI.


This study aimed to identify factors associated with NCI using a large and diverse sample of PLWH and build a nomogram based on demographic, clinical, and behavioral variables.


We performed Bayesian network analysis using a supervised learning technique with the Markov Blanket (MB) algorithm. Logistic regression was also conducted to obtain the adjusted regression coefficients to construct the nomogram.


Among 1,307 participants, 21.6% were neurocognitively impaired. During the MB analysis, age provided the highest amount of mutual information (0.0333). Logistic regression also showed that old age (>50 vs. ≤50 years) had the strongest association (OR=2.77, 95% CI=1.99-3.85) with NCI. The highest possible points on the nomogram were 626, translated to a nomogram-predicted probability of NCI to be approximately 0.95. The receiver operating characteristic (ROC) curve's concordance index was 0.75, and the nomogram's calibration plot exhibited an excellent agreement between observed and predicted probabilities.


The nomogram used variables that can be easily measured in clinical settings and, thus, easy to implement within a clinic or web-interface platform. The nomogram may help clinicians screen for patients with a high probability of having NCI and thus needing a comprehensive neurocognitive assessment for early diagnosis and appropriate management.

Keywords: HIV, Neurocognition, Nomogram, Risk factors, Screening, Markov Blanket.


The development of highly active combination antiretroviral therapy (cART) has resulted in a remarkable decline in HIV-associated morbidity and mortality [1]. HIV has become a chronic disease with a life expectancy of the medication-compliant infected population approaching the uninfected population [2]. With the changing course of HIV infection, the pattern of HIV-associated neurocognitive disorders (HAND) has also altered [3]. The adverse consequences of HIV on the central nervous system have reduced in severity but are still prevalent as milder forms of neurocognitive impairment (NCI) [4, 5]. Even in milder forms, NCI is disabling and constitutes a public health issue due to its adverse effect on everyday functioning. NCI has been found to be associated with poor medication management [6], low self-efficacy for healthcare interactions [7], unemployment [8], poor health-related quality of life [9], and higher mortality [10].

The pathogenesis of NCI in people living with HIV (PLWH) is multifaceted, including direct viral replication, chronic inflammation, treatment-related adverse effects, comorbidities, and aging, and is not well recognized [11]. A number of risk factor associations with NCI have been studied in the HIV-infected population. However, the studies have generated inconsistent results. While some studies reported older age, female gender, Hispanic ethnicity, substance use, comorbidities (depression, hepatitis-C co-infection, metabolic disorders, and anemia), high viral load, and low CD4 T-cell counts to be positively associated with NCI in PLWH [12-21], others reported contradicting results [22-28]. The findings' inconsistencies may be due to methodological differences, including differences in study population and eligibility criteria, small sample size, differences in testing modalities, and a variable degree of control for confounding factors. There is still a need for a comprehensive assessment of etiological factors to develop an optimal prediction model for NCI in PLWH.

Neuropsychologic testing remains the “gold standard” of NCI diagnosis; however, it is time consuming, costly, and requires interpretation by a neuropsychologist. Thus, a brief and readily available screening tool is desirable in clinical practice. The current screening tools such as CogState battery, revised HIV dementia scale, and Montreal Cognitive Assessment are either robust in detecting more severe forms of impairment (e.g., HIV-associated dementia) [29] or did not have good screening accuracy for HAND [30]. Furthermore, these screening tools require neurocognitive testing for implementation. Given that demographic and clinical data can be readily collected, they may be valuable in developing user-friendly nomograms to predict NCI in PLWH. Nomograms are a user-friendly pictorial representation of complex statistical models that estimate individualized risk probabilities of particular events based on patient and disease characteristics. Nomograms have been widely studied and used in cancer research [31]. However, to our knowledge, they have not been utilized for neuropsychological assessments. Nomograms could potentially serve as adjunct procedures when determining whether a patient may require further neuropsychological assessments. Our study's first objective was to identify factors associated with NCI using a large and diverse sample of PLWH. The second objective of our study was to build a user-friendly predictive tool (nomogram) based on demographic, clinical, and behavioral variables to identify PLWH at risk of NCI.


2.1. Data Source and Participants

The CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study baseline database was used to examine risk factors associated with NCI in HIV patients and to develop the nomogram. The CHARTER study was a prospective observational study conducted with the primary aim to determine how central and peripheral nervous system complications of HIV are affected by different histories and regimens of antiretroviral therapy. Participants were enrolled between 2003 to 2007, with minimal exclusion criteria (i.e., if they declined to participate or if their screening interviewer doubted their ability to participate), at six participating sites, including Johns Hopkins University, Mt. Sinai School of Medicine, University of California San Diego, University of Texas Medical Branch, University of Washington, and Washington University. The study concluded in 2015, and in addition to collecting demographic and clinical data, participants received comprehensive neuro-medical, neurocognitive, and laboratory examinations [32, 33].

2.2. Variables

The primary outcome was neurocognitive impairment (NCI). NCI was ascertained at enrollment through a comprehensive neurocognitive test battery covering seven domains, abstraction/executive functioning, speed of information processing, attention and working memory, learning, memory, verbal fluency, and motor functioning. Individual raw test scores were converted to demographically corrected standard scores (T-scores), which were then averaged to generate the global T-score. The best available normative standards were used to correct the effects of age, education, sex, and ethnicity, as appropriate. Details of the normative standards are given elsewhere [34]. An impaired neurocognitive status was assigned to those with a global T-score value of <40 [35-37]. We did not further classify NCI into mild, moderate, or severe because this categorization is partially based on activities of daily living (ADLs), and ADLs were already included as predictors in the model.

Based on prior literature and biological plausibility, the independent variables included in the analyses were demographic factors (age, education, gender, race, ethnicity and employment), HIV-related factors (disease severity, duration of HIV infection, antiretroviral (ARV) drug use, CD4 nadir, current CD4 and plasma viral loads), activities of daily living (eating, bathing, dressing, using the toilet and taking medication), comorbidities (depressive symptoms assessed through Beck depression index (BDI-II), anemia, syphilis, history of head injury, history of coma, history of seizures, diabetes, hypertension using ICD-9 codes, hyperlipidemia, hypercholesterolemia, viral hepatitis and any AIDS-defining comorbidity), laboratory measures (urine proteins, hepatitis C viral loads, serum glucose, blood urea nitrogen, serum creatinine, serum sodium, serum chloride, serum potassium, serum calcium, serum total protein, serum bilirubin, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum hemoglobin, blood monocyte percent), medication history (antidiabetics, lipid lowering drugs, psychotropic medication) and substance use (history of alcohol, opiate, hallucinogen, inhalant, sedative, methamphetamine, cannabis and cocaine use). Among the activities of daily living, selected variables (eating, bathing, dressing, using the toilet, and taking medication) were included as they were universally applicable to all the participants. The severity of HIV infection was measured using the 1993 Centers for Disease Control and Prevention (CDC) classification system. The variable “any AIDS-defining comorbidity” was categorized “yes” if the participant had a diagnosis of any of Cryptococcus (extrapulmonary), cytomegalovirus disease (other than liver, spleen, or nodes), cytomegalovirus retinitis, HIV-related encephalopathy, herpes simplex, disseminated histoplasmosis, Kaposi sarcoma, Burkitt's lymphoma, disseminated mycobacterium avium complex, any site mycobacterium tuberculosis, pneumocystis carinii pneumonia, recurrent pneumonia or progressive multifocal leukoencephalopathy. No exclusions were made based on any comorbidity to enable the nomogram to detect any neurocognitive impairment (HIV-related and others).

2.3. Statistical Analyses

Descriptive statistics were performed for categorical (frequencies and percentages) and numeric variables (means, medians, and standard deviations) to assess the sample's overall demographic and clinical characteristics. All continuous clinical variables (duration of HIV infection, CD4 nadir, current CD4, plasma viral loads, depressive symptoms assessed through BDI-II, urine proteins, hepatitis C viral loads, serum glucose, blood urea nitrogen, serum creatinine, serum sodium, serum chloride, serum potassium, serum calcium, serum total protein, serum bilirubin, serum AST, serum ALT, serum hemoglobin and blood monocyte percent) were converted to meaningful categorical variables using standard clinical cutoffs taken from MedlinePlus [38] (Table S1). A cutoff value of 50 (≤50 years or >50 years) was used to categorize age as a binary variable as nearly half of PLWH in the US are aged 50 years or older [39]. The duration of HIV infection was categorized as ≤15 years or >15 years based on the median. Chi-squared tests were performed to determine the outcome variable's association with individual predictors. A Bayesian network analysis using a supervised learning technique with the Markov Blanket (MB) algorithm was employed for predictive modeling. Bayesian networks are non-parametric probabilistic models that identify predictors qualitatively through a graphical diagram with nodes (representing variables) and edges (arrows representing relationships) [40]. Bayesian network analyses do not require conventional statistical assumptions, and they can handle a large number of predictors [40, 41]. Furthermore, compared to standard regression models in which the correlation between the variables leads to multicollinearity and lack of robustness of model fitting, Bayesian networks leverage the mutual correlation between variables to define the conditional probability distributions [42]. The MB is the smallest subset of the Bayesian network characterized by the property that all variables outside the MB could be deleted without influence on the target node and thus will have no impact on the accuracy of classification [43]. Mutual information was generated between the nodes (independent variables) and the target node (outcome variable). K-fold (10-fold) cross-validation was used to evaluate network performance. Given the broad age range, a sub-analysis using Bayesian Network was conducted and an MB model was generated separately for participants less than 50 years old and 50 years or older to investigate age differences.

With NCI as the outcome variable (binary), multivariable logistic regression analysis was conducted to obtain the adjusted regression coefficients for the independent variables identified through the Bayesian network analysis. All nine variables identified by the Bayesian network analyses were included in the multivariable logistic model. To these, we added one demographic variable (race/ethnicity) that had dropped out in the network analysis but was associated with the outcome at 2-sided α=0.1 in univariable logistic regression. A nomogram was built using techniques described by Lasonos et al., Brittain E, and Zhang et al. [44-46]. Briefly, the regression coefficients from the multivariable logistic regression were converted into scores ranging from 0 to 100 points. The variable with the largest absolute regression coefficient was assigned 100 points. The remaining variables were assigned a smaller number of points proportional to the value of their regression coefficient. The points from all the variables were added together, and the total score was then converted into the corresponding probability of having NCI. The nomogram's predictive accuracy (discrimination) was measured via a concordance index (c-index). The nomogram's calibration was assessed by reviewing the plot of predicted probabilities from the nomogram versus the actual probabilities. The analyses were performed using SAS 9.4 (SAS Institute, Inc., Cary, NC) software and R software-3.5.0 (RMS package).


A total of 1610 participants were enrolled in the CHARTER study; of these, 1,595 participants (99.1%) had complete baseline data on the outcome variable. After excluding 288 participants (18.0%) with missing information on covariates of interest, the final sample analyzed included 1,307 participants. Most participants were under 50 years of age (81.6%), males (77.4%), and non-Hispanic African Americans (47.4%) (Table S1). At baseline, 21.6% of participants had global T-scores under 40 (impaired), and 65.1% were using highly active antiretroviral therapy (HAART). Furthermore, among those who were older than 50 years old, 41.2% were neurocognitively impaired compared to 17.2% of those at or below 50 years of age (Table S1).

The Bayesian network analysis identified that neurocognitive impairment has a direct probabilistic relationship, in descending order of mutual information, with age, lifetime cocaine use, current employment status, difficulty in bathing, dressing, eating, or using the toilet, impaired use of hands, diagnosis of abnormally high cholesterol, current psychotropic medication use, presence of any AIDS-defining illness and lifetime history of stroke (Fig. 1).

Fig. (1). Markov Blanket model with mutual information between neurocognitive impairment (central node) and other covariates.

The number at the top (within each box) in Fig. (1) is the mutual information (predictive importance) between the outcome (neurocognitive impairment shown in the center) and each covariate. The middle number is the relative mutual information with regard to the child node (i.e., the amount of uncertainty reduced regarding the parent node by knowing the child node). The bottom number is the relative mutual information with regard to the parent node (i.e., the amount of uncertainty reduced regarding the child node by knowing the parent node). The arrows’ direction is dependent on computational complexity and does not reflect causality.

Among the variables included in the Markov blanket of the target variable (neurocognitive status), age provided the highest amount of mutual information (0.0333) and lifetime history of stroke the least (0.0088). Specifically, by knowing age, the uncertainty regarding neurocognitive status was reduced by 4.4% on average (Fig. 1). The K-fold cross-validation yielded an overall accuracy of 78%. The MB model generated for the younger participants (<50 years) showed that, except for history of stroke, all other predictors remained the same (Fig. S1) as the overall model, whereas the MB model for older participants (≥50 years) included the history of stroke but not four other variables (Fig. S2).

Results of the multiple logistic regression indicated age to have the strongest association with NCI. Specifically, the adjusted odds ratio of NCI among those above 50 years of age was 2.77 times (95% CI=1.99-3.85) those at or below 50 years of age (Table 1).

Table 1.
Crude and adjusted Odds Ratios (OR) for neurocognitive impairment by selected variables among HIV-infected participants of CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study (n=1,307).
Characteristics n (%) Neurocognitive Impairment
Crude OR (95% CI) Adjusted OR (95% CI)1
Age (years)*
1,067 (81.6)
240 (18.4)
3.37 (2.49 – 4.56)
2.77 (1.99 – 3.85)
Non-Hispanic African American
Non-Hispanic White
620 (47.4)
537 (41.1)
116 (8.9)
34 (2.6)
1.51 (1.14 – 2.01)
1.86 (1.18 – 2.93)
1.95 (0.91 – 4.20)
1.45 (1.04 – 2.02)
1.99 (1.22 – 3.28)
2.09 (0.90 – 4.88)
Currently employed*
952 (72.8)
355 (27.2)
0.43 (0.31 – 0.61)
0.48 (0.33 – 0.71)
History of high cholesterol
1,039 (79.5)
268 (20.5)
2.12 (1.57 – 2.85)
1.48 (1.06 – 2.08)
Current use of psychotropic medication*
547 (41.8)
760 (58.2)
1.91 (1.44 – 2.54)
1.42 (1.04 – 1.94)
History of stroke
1,232 (94.3)
75 (5.7)
2.74 (1.69 – 4.43)
2.22 (1.29 – 3.81)
Any AIDS defining illness2*
857 (65.6)
450 (34.4)
1.80 (1.37 – 2.35)
1.43 (1.06 – 1.93)
Lifetime cocaine use
736 (56.3)
571 (43.7)
0.45 (0.34 - 0.60)
0.47 (0.34 – 0.64)
Difficulty eating, dressing, bathing, or using the toilet*
1,098 (84.0)
209 (15.9)
2.39 (1.74 – 3.29)
1.83 (1.28 – 2.62)
Impaired use of hands*
1,141 (87.3)
166 (12.7)
2.48 (1.75 – 3.51)
1.90 (1.28 – 2.81)
1,012 (77.4)
295 (22.6)
1.19 (0.88 – 1.63)
ARV use3
No Current ARVs
ARV Naïve
851 (65.1)
93 (7.1)
175 (13.4)
188 (14.4)
0.99 (0.60 – 1.63)
0.57 (0.37 – 0.88)
0.36 (0.22 – 0.58)
Duration of HIV infection (years)*
1,007 (77.1)
300 (22.9)
1.22 (0.90 – 1.65)
Lifetime = ever
Ref = Reference category
1Each variable is adjusted for all other variables in the table for which an adjusted odds ratio has been calculated.
2It includes diagnosis of Cryptococcus (extra pulmonary), Cytomegalovirus disease (other than liver, spleen or nodes) Cytomegalovirus retinitis, HIV related encephalopathy, herpes simplex, disseminated histoplasmosis, Kaposi sarcoma, Burkitt’s lymphoma, disseminated mycobacterium avium complex, any site mycobacterium tuberculosis, Pneumocystis carinii pneumonia, recurrent pneumonia and Progressive multifocal leukoencephalopathy.
3HAART= Using highly active antiretroviral therapy at baseline visit and Non-HAART= using antiretroviral medication but not a HAART regimen at baseline.
*Variables measured at baseline visit
The last three variables are listed in the table for completeness

History of high cholesterol, current psychotropic drug use, history of stroke, history of any AIDS-defining illness, current difficulty eating, dressing, bathing, or using the toilet, and impaired use of hands were also positively associated with NCI (Table 1). Those employed and those who reported a history of cocaine use had lower odds of NCI (Table 1). Since age had the highest adjusted regression coefficient (β=1.02; equivalent to OR=2.77 after exponentiation), it was assigned 100 points in the nomogram (Fig. 2).

The points per variable are added together for each person and then converted into a probability of having NCI. For example, for a non-Hispanic white, aged below 50 years, with no employment, current use of psychotropic drugs, AIDS-defining illness, history of stroke, impaired use of hands and difficulty eating, dressing, bathing, or using the toilet and positive histories of high cholesterol and lifetime cocaine use will have total points of 146 converted to a probability of approximately 0.13. The highest possible points on the nomogram were 626, translated to a nomogram-predicted probability of NCI to be approximately 0.95. The receiver operating characteristic (ROC) curve's concordance index was 0.75 (Fig. 3a), and there was excellent agreement between observed and predicted probabilities, as shown by the nomogram's calibration plot (Fig. 3b).

Fig. (2). Nomogram for predicting the probability of neurocognitive impairment among HIV-infected participants of the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study (n=1,307).
Fig. (3a). Receiver operating characteristic (ROC) curve; AUC= 0.7473.
Fig. (3b). Calibration plot of observed versus nomogram predicted probabilities.


Despite the availability of potent antiretroviral medications, mild to moderate neurocognitive impairment persists in PLWH [33]. There is limited agreement in the literature about the risk factors for NCI in PLWH. Our first objective was to use a large sample of HIV-infected patients with NCI status assessed through a comprehensive battery of neuropsychological tests to examine the factors associated with NCI. The search for an optimal screening tool for NCI in PLWH is still ongoing. Traditional neuropsychological test batteries are lengthy, time-consuming, and require trained psychometrists and thus may not be feasible for use in primary care clinics. We hypothesized that the probability of having HIV-related NCI during a clinic visit may be assessed using a predictive tool based on demographic, behavioral, and clinical factors and thus created a nomogram.

The results of both Bayesian network analysis and multivariable logistic regression demonstrated age to be the most important predictor of NCI (highest mutual information and highest adjusted odds ratios). As we used corrected (adjusted for age, education, and other variables) T-scores based on standardized normative data, the association specifically embodies changes beyond the normal age-related neurocognitive function. The association between age and NCI among PLWH is crucial as HIV has been found to lead to premature and accelerated aging [47]. However, as we did not use an HIV-negative control group, we cannot comment on the interaction between HIV status and age in association with NCI. Our finding regarding age is in line with a recent US-based study that found older age (>50 years) to be associated with weaker overall cognitive performance among PLWH [48]. Another recent systematic review of HIV-infected adults reported that the odds ratio (OR) of having NCI among older participants compared to their younger counterparts varied between 1.18 and 4.8 [49]. The T-scores correction might explain why education dropped out of the model and nomogram during analyses.

Interestingly, cocaine use was associated with lower odds of NCI (OR=0.46, 95% CI=0.33-0.63). As we had combined lifetime cocaine abuse and lifetime cocaine dependence to generate the cocaine use variable, we may have underestimated the findings in active drug users. A possible explanation is that some participants might have used cocaine only in the past, and this may account for the reversal of cocaine use effects. The literature exhibits mixed results regarding the association between NCI and cocaine use among PLWH. Meade et al. did not find any association between current (past three months) cocaine use and a global neurocognitive measure (Global Deficit Scores); however, they did find higher impairment in processing speed and executive functioning among cocaine users compared to non-users [24]. Similarly, Attonito et al. did not find any association between cocaine use and neurocognition among 370 HIV-positive participants living in Florida [50]. Interestingly, another study using CHARTER data combined lifetime and current use of cocaine to define cocaine use variable, and although it did not detect any association between global impairment and cocaine use, they did report a weak association between cocaine use and improved verbal fluency [51].

Although limited research has been done on the topic, the inverse association between employment and NCI found in our study is consistent with the literature. Blackstone et al. demonstrated higher unemployment among those with NCI, and Rabkin et al. found that impairment in executive functioning represented significant employment barriers in HIV-infected men [52, 53]. Not only may NCI render PLWH unable to be efficiently employed, but unemployment itself may also reduce neurocognitive ability, as being employed provides cognitive stimulation, facilitating enhanced cognitive functioning [54].

We ascertained difficulty in daily living by combining difficulty in bathing, dressing, eating, or using the toilet and found a positive association with NCI. The finding is not surprising, as an ample body of literature indicates that HIV-associated neurocognitive disorders are a significant risk factor for everyday functioning decline [6-8, 55]. Our result that Hispanics and non-Hispanic Whites have higher adjusted odds of NCI than non-Hispanic African Americans is generally in contrast with prior reports of higher impairment among African Americans [56-58]. However, prior studies differ from ours regarding the included samples (gender or ART use specific) and NCI measures. Our finding may be sample dependent as it was a multicenter study and had voluntary participation; however, stratification by individual sites showed similar findings across sites (results not shown). Heaton et al., in a longitudinal analysis using CHARTER data, also found higher neurocognitive decline (RR=2.35) among Hispanics compared to non-Hispanics (Whites and African Americans combined). Previous studies have demonstrated that Hispanic adults are diagnosed late for HIV and thus have a delayed HIV care initiation [59, 60], which may be an explanation of our finding.

Among the comorbidities, we found impaired use of hands, abnormally high cholesterol, current psychotropic drug use, presence of any AIDS-defining illness, and lifetime history of stroke to be positively associated with NCI. The specific reasons for hand impairment were not available. Hand impairment may result from HIV-induced brain injury, aging, external trauma, systemic disease, or other CNS infections and vascular diseases [61-64]. Thus, in some participants with hand impairment, poor motor-domain performance may not truly represent NCI and may need further evaluation. Previous studies have consistently found hypercholesterolemia to be positively associated with NCI in PLWH. A recent longitudinal study using CHARTER data found that participants with declining cognition exhibited a higher baseline cholesterol/HDL ratio compared to patients with stably normal cognition [65]. Another longitudinal study established elevated cholesterol to be an independent risk factor for cognitive decline in ART-adherent HIV-infected men [66]. The most plausible explanation for this association may be HIV-induced endothelial dysfunction leading to cholesterol oxidation and thus sub-clinical cerebrovascular damage [67-69]. Psychotropic drug use may commonly indicate a diagnosis of anxiety, depression, psychosis, or sleep disorders, and hence an association with poor cognition. Although the literature is limited for other conditions, depression has been amply studied and, according to a recent comprehensive review, was associated positively with NCI in PLWH [70]. Depression may act directly or indirectly through poor ARV adherence to affect neurocognition in PLWH [70]. The presence of AIDS-defining comorbidities indicates higher severity of HIV infection and is rather plausibly associated with NCI. In addition to HIV infection acting itself, certain AIDS-defining infections such as HIV-related encephalopathy, disseminated histoplasmosis, disseminated mycobacterium avium complex, and progressive multifocal leukoencephalopathy may directly affect the brain leading to impairment [71]. The positive association between AIDS-defining comorbidities and HIV disease severity may explain why, when this variable was included in the Bayesian or logistic regression models, other variables such as HIV duration and the viral load dropped out.

Specialists have recommended conducting routine and regular screening for NCI for early detection, treatment adjustment, and management in PLWH. However, most screening tools are based on neurocognitive testing that requires clinicians to be suitably trained in its administration and interpretation. Furthermore, currently available screening tools are generally unable to detect milder forms of NCI [72, 73]. We created a nomogram based on easily recordable demographic, clinical, and behavioral factors to serve as a user-friendly screening tool and predict NCI in PLWH. There is one study by Cysique et al. that attempted to develop a screening algorithm with demographic and clinical factors using support vector machine methodology [74] using a sample of 97 HIV-infected individuals on CART and with advanced HIV infection. The study included age, current CD4 cell count, past central nervous system HIV‐related diseases, and current treatment duration in the algorithm. However, they did not convert their algorithm into a ready-to-use screening tool. Another study by Muñoz-Moreno et al. used a tree-structured approach and created four classification models to predict NCI in PLWH and identified age, employment status, CD4 cell count, highest viral load, comorbidities, HIV duration, and duration of current treatment as potential predictors [75]. However, their statistical approach (classification and regression trees) differed from our Bayesian network analysis.

Our study had some limitations. Although exclusion criteria were kept to a minimum to maximize generalizability, this was a clinic-based and volunteer sample. The proposed nomogram needs to be validated in other PLWH samples. This study is one of its kind, conducted at six centers in the US with information available on a wide range of demographic, behavioral, clinical, and laboratory measures and NCI status assessed through a comprehensive neuropsychological test battery. Some individuals with medical pathologies other than NCI could have ADL impairment. Thus, a disadvantage of including ADLs as a predictor of NCI is a potentially higher number of false positives during the screening nomogram. However, an advantage is that more individuals with NCI would have been false negatives had ADLs not been included as a predictor.


In conclusion, we investigated factors associated with NCI in PLWH and developed a novel nomogram to predict NCI in the HIV-infected population. The nomogram used variables that can be easily measured in clinical settings and, thus, easy to implement within a clinic or web-interface platform. Our goal with such a tool is to help clinicians predict specific patients who might have a high probability of NCI and be further evaluated by a comprehensive neuropsychological examination resulting in timely diagnosis and appropriate management. Future research should focus on external validation of the nomogram in different populations to assess broader applicability. Distinct nomograms may also be developed for specific patient subgroups such as older and younger patients.


The conceptualization and designing of the study were performed by ZN, HSF, LB, PM, and CMA. Data were acquired by HSF. Data analysis was performed by ZN, LB, CSW, and JM. The manuscript was drafted by ZN, LB, and PM. Review and revision of the article were performed by ZN, HSF, LB, CSW, PM, CMA, and JM. All authors have read the manuscript and approved its contents.


This study was approved by the University of Nebraska Medical Center's institutional Review Board (Protocol #282-13-EP). All the procedures were approved by the Human Subjects Protection Committees of each participating institution.


No animals were used in this research. All human research procedures were followed in accordance with the ethical standards of the committee responsible for human experimentation (institutional and national), and with the Helsinki Declaration of 1975, as revised in 2013.


Written and oral informed consent was obtained from the patient and his parents to publish his records.


The data supporting the findings of the article are available by submitting a request and signing a data use agreement at


The study was conducted under the auspices of the NNTC, which is supported by the National Institutes of Health (NIH) under Award Numbers U24MH100925, U24MH100928, U24MH100929, U24MH100930, and U24MH100931.


We confirm that the STROBE guidelines from the EQUATOR network were followed for our study.


The authors declare no conflict of interest, financial or otherwise.


The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or NNTC.


Supplementary material is available on the publishers Website along with the published article.


Trickey A, May MT, Vehreschild J, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: A collaborative analysis of cohort studies. Lancet HIV 2017; 4(8): e349-56.
Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect Dis 2013; 13(11): 976-86.
McArthur JC. HIV dementia: An evolving disease. J Neuroimmunol 2004; 157(1-2): 3-10.
Saylor D, Dickens AM, Sacktor N, et al. HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment. Nat Rev Neurol 2016; 12(4): 234-48.
Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24(9): 1243-50.
Thames AD, Arentoft A, Rivera-Mindt M, Hinkin CH. Functional disability in medication management and driving among individuals with HIV: A 1-year follow-up study. J Clin Exp Neuropsychol 2013; 35(1): 49-58.
Morgan EE, Woods SP, Iudicello JE, Grant I, Villalobos J. HIV Neurobehavioral Research Program (HNRP) Group. HIV Neurobehavioral Research Program (HNRP) Group Poor self-efficacy for healthcare provider interactions among individuals with HIV-associated neurocognitive disorders. J Clin Psychol Med Settings 2019; 26(1): 13-24.
Marquine MJ, Flores I, Kamat R, et al. A composite of multisystem injury and neurocognitive impairment in HIV infection: Association with everyday functioning. J Neurovirol 2018; 24(5): 549-56.
Jones JD, Kuhn T, Levine A, et al. Changes in cognition precede changes in HRQoL among HIV+ males: Longitudinal analysis of the multicenter AIDS cohort study. Neuropsychology 2019; 33(3): 370-8.
Banerjee N, McIntosh RC, Ironson G. Impaired neurocognitive performance and mortality in HIV: Assessing the prognostic value of the HIV-dementia scale. AIDS Behav 2019; 23(12): 3482-92.
Caruana G, Vidili G, Serra PA, et al. The burden of HIV-associated neurocognitive disorder (HAND) in post-HAART era: A multidisciplinary review of the literature. Eur Rev Med Pharmacol Sci 2017; 21(9): 2290-301.
Coban H, Robertson K, Smurzynski M, et al. Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen. AIDS 2017; 31(11): 1565-71.
Paolillo EW, Pasipanodya EC, Moore RC, et al. Cumulative burden of depression and neurocognitive decline among persons with HIV: A longitudinal study. J Acquir Immune Defic Syndr 2020; 84(3): 304-12.
Miller TR, Weiss JJ, Bräu N, Dieterich DT, Stivala A, Rivera-Mindt M. Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin. J Neurovirol 2017; 23(2): 260-72.
Kallianpur AR, Wang Q, Jia P, et al. Anemia and red blood cell indices predict HIV-associated neurocognitive impairment in the highly active antiretroviral therapy era. J Infect Dis 2016; 213(7): 1065-73.
Monnig MA, Kahler CW, Lee H, et al. Effects of smoking and alcohol use on neurocognitive functioning in heavy drinking, HIV-positive men who have sex with men. AIDS Care 2016; 28(3): 300-5.
Swanta N, Aryal S, Nejtek V, Shenoy S, Ghorpade A, Borgmann K. Blood-based inflammation biomarkers of neurocognitive impairment in people living with HIV. J Neurovirol 2020; 26(3): 358-70.
Weber V, Radeloff D, Reimers B, et al. Neurocognitive development in HIV-positive children is correlated with plasma viral loads in early childhood. Medicine (Baltimore) 2017; 96(23): e6867.
Marquine MJ, Heaton A, Johnson N, et al. Differences in neurocognitive impairment among HIV-infected Latinos in the United States. J Int Neuropsychol Soc 2018; 24(2): 163-75.
Yu B, Pasipanodya E, Montoya JL, et al. Metabolic syndrome and neurocognitive deficits in HIV infection. J Acquir Immune Defic Syndr 2019; 81(1): 95-101.
Rubin LH, Neigh GN, Sundermann EE, Xu Y, Scully EP, Maki PM. Sex differences in neurocognitive function in adults with HIV: Patterns, predictors, and mechanisms. Curr Psychiatry Rep 2019; 21(10): 94.
de Almeida SM, de Pereira AP, Pedroso MLA, et al. Neurocognitive impairment with hepatitis C and HIV co-infection in Southern Brazil. J Neurovirol 2018; 24(3): 339-49.
Douglas-Newman KR, Smith RV, Spiers MV, Pond T, Kranzler HR. Effects of recent alcohol consumption level on neurocognitive performance in HIV+ individuals. Addict Disord Their Treat 2017; 16(3): 95-107.
Meade CS, Towe SL, Skalski LM, Robertson KR. Independent effects of HIV infection and cocaine dependence on neurocognitive impairment in a community sample living in the southern United States. Drug Alcohol Depend 2015; 149: 128-35.
Tymchuk S, Gomez D, Koenig N, Gill MJ, Fujiwara E, Power C. Associations between depressive symptomatology and neurocognitive impairment in HIV/AIDS. Can J Psychiatry 2018; 63(5): 329-36.
Burlacu R, Umlauf A, Luca A, et al. Sex-based differences in neurocognitive functioning in HIV-infected young adults. AIDS 2018; 32(2): 217-25.
Valcour V, Paul R, Neuhaus J, Shikuma C. The effects of age and HIV on neuropsychological performance. J Int Neuropsychol Soc 2011; 17(1): 190-5.
Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 2011; 17(2): 176-83.
Carroll A, Brew B. HIV-associated neurocognitive disorders: Recent advances in pathogenesis, biomarkers, and treatment. F1000 Res 2017; 6: 312.
Kim WJ, Ku NS, Lee YJ, et al. Utility of the Montreal Cognitive Assessment (MoCA) and its subset in HIV-associated neurocognitive disorder (HAND) screening. J Psychosom Res 2016; 80: 53-7.
Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: More than meets the eye. Lancet Oncol 2015; 16(4): e173-80.
Charter Study description
Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: Charter Study. Neurology 2010; 75(23): 2087-96.
Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. J Neurovirol 2011; 17(1): 3-16.
Cassol E, Misra V, Morgello S, Gabuzda D. Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection. J Neuroimmune Pharmacol 2013; 8(5): 1087-97.
Lyons JL, Uno H, Ancuta P, et al. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr 2011; 57(5): 371-9.
Mindt MR, Miranda C, Arentoft A, et al. Aging and HIV/AIDS: Neurocognitive implications for older HIV-positive Latina/o adults. Behav Med 2014; 40(3): 116-23.
MedlinePlus Medical tests 2020. Available from:
Lee SM, Abbott P, Johantgen M. Logistic regression and Bayesian networks to study outcomes using large data sets. Nurs Res 2005; 54(2): 133-8.
Witteveen A, Nane GF, Vliegen IMH, Siesling S, IJzerman MJ. Comparison of logistic regression and Bayesian networks for risk prediction of breast cancer recurrence. Med Decis Making 2018; 38(7): 822-33.
Pourret O, Naïm P, Marcot B. Bayesian networks: A practical guide to applications 2008.
Liu S, Zhang R, Shang X, Li W. Analysis for warning factors of type 2 diabetes mellitus complications with Markov blanket based on a Bayesian network model. Comput Methods Programs Biomed 2020; 188: 105302.
Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 2008; 26(8): 1364-70.
Zhang Z, Kattan MW. Drawing Nomograms with R: Applications to categorical outcome and survival data. Ann Transl Med 2017; 5(10): 211.
Brittain E. Probability of coronary heart disease developing. West J Med 1982; 136(1): 86-9.
Aung HL, Kootar S, Gates TM, Brew BJ, Cysique LA. How all-type dementia risk factors and modifiable risk interventions may be relevant to the first-generation aging with HIV infection? Eur Geriatr Med 2019; 10: 227-38.
Cohen RA, Gullett JM, Porges EC, et al. Heavy Alcohol Use and Age Effects on HIV-Associated Neurocognitive Function. Alcohol Clin Exp Res 2019; 43(1): 147-57.
Aung HL, Aghvinian M, Gouse H, et al. Is there any evidence of premature, accentuated and accelerated aging effects on neurocognition in people living with HIV? A systematic review. AIDS Behav 2020; 1-44.
Attonito JM, Dévieux JG, Lerner BD, Hospital MM, Rosenberg R. Exploring substance use and HIV treatment factors associated with neurocognitive impairment among people living with HIV/AIDS. Front Public Health 2014; 2: 105.
Byrd DA, Fellows RP, Morgello S, et al. Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr 2011; 58(2): 154-62.
Rabkin JG, McElhiney M, Ferrando SJ, Van Gorp W, Lin SH. Predictors of employment of men with HIV/AIDS: A longitudinal study. Psychosom Med 2004; 66(1): 72-8.
Blackstone K, Moore DJ, Franklin DR, et al. Defining neurocognitive impairment in HIV: Deficit scores versus clinical ratings. Clin Neuropsychol 2012; 26(6): 894-908.
Fazeli PL, Woods SP, Heaton RK, et al. An active lifestyle is associated with better neurocognitive functioning in adults living with HIV infection. J Neurovirol 2014; 20(3): 233-42.
Heaton R K, Marcotte T D, Rivera-Mindt M, et al. HNRC Group The impact of HIV-associated neuropsychological impairment on everyday functioning 2004.
Winston A, Arenas-Pinto A, Stöhr W, et al. Neurocognitive function in HIV infected patients on antiretroviral therapy. PLoS One 2013; 8(4): e61949.
Maki PM, Rubin LH, Valcour V, et al. Cognitive function in women with HIV: Findings from the Women’s Interagency HIV Study. Neurology 2015; 84(3): 231-40.
Koenig N, Fujiwara E, Gill MJ, Power C. Montreal cognitive assessment performance in HIV/AIDS: Impact of systemic factors. Can J Neurol Sci 2016; 43(1): 157-62.
Dennis AM, Napravnik S, Seña AC, Eron JJ. Late entry to HIV care among Latinos compared with non-Latinos in a southeastern US cohort. Clin Infect Dis 2011; 53(5): 480-7.
Chen NE, Gallant JE, Page KR. A systematic review of HIV/AIDS survival and delayed diagnosis among Hispanics in the United States. J Immigr Minor Health 2012; 14(1): 65-81.
Schrack JA, Jacobson LP, Althoff KN, et al. Multicenter AIDS Cohort Study. Effect of HIV-infection and cumulative viral load on age-related decline in grip strength. AIDS 2016; 30(17): 2645-52.
Behroozmand R, Johari K. Sensorimotor impairment of speech and hand movement timing processing in Parkinson’s disease. J Mot Behav 2019; 51(5): 561-71.
Landelle C, El Ahmadi A, Kavounoudias A. Age-related impairment of hand movement perception based on muscle proprioception and touch. Neuroscience 2018; 381: 91-104.
Young A, Namas R, Dodge C, Khanna D. Hand impairment in systemic sclerosis: Various manifestations and currently available treatment. Curr Treatm Opt Rheumatol 2016; 2(3): 252-69.
Khuder SS, Chen S, Letendre S, et al. Impaired insulin sensitivity is associated with worsening cognition in HIV-infected patients. Neurology 2019; 92(12): e1344-53.
Mukerji SS, Locascio JJ, Misra V, et al. Lipid profiles and APOE4 allele impact midlife cognitive decline in HIV-infected men on antiretroviral therapy. Clin Infect Dis 2016; 63(8): 1130-9.
Chen Z, Ichetovkin M, Kurtz M, et al. Cholesterol in human atherosclerotic plaque is a marker for underlying disease state and plaque vulnerability. Lipids Health Dis 2010; 9: 61.
Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: Relationship to in vivo coagulation and immune activation. Blood 2010; 115(2): 161-7.
Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109(23)(Suppl. 1): III27-32.
Rubin LH, Maki PM. HIV, depression, and cognitive impairment in the era of effective antiretroviral therapy. Curr HIV/AIDS Rep 2019; 16(1): 82-95.
Paul RH, Laidlaw DH, Tate DF, et al. Neuropsychological and neuroimaging outcome of HIV-associated progressive multifocal leukoencephalopathy in the era of antiretroviral therapy. J Integr Neurosci 2007; 6(1): 191-203.
Antinori, A.; Arendt, G.; Grant, I.; Letendre, S.; Muñoz-Moreno, J. A.; Eggers, C.; Brew, B.; Brouillette, M.; Bernal-Cano, F. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: A consensus report of the mind exchange program. Clin Infect Dis 2013; 56: 1004-17.
Joska JA, Witten J, Thomas KG, et al. A comparison of five brief screening tools for HIV-associated neurocognitive disorders in the USA and South Africa. AIDS Behav 2016; 20(8): 1621-31.
Cysique LA, Murray JM, Dunbar M, Jeyakumar V, Brew BJ. A screening algorithm for HIV-associated neurocognitive disorders. HIV Med 2010; 11(10): 642-9.
Muñoz-Moreno JA, Pérez-Álvarez N, Muñoz-Murillo A, et al. Classification models for neurocognitive impairment in HIV infection based on demographic and clinical variables. PLoS One 2014; 9(9): e107625.